Clinical Trials Browser

Phase 1/2 × OTHER × Infliximab × Clear all

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1/2 Active not recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT02638701 2025-07-08

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Phase 1/2 Recruiting

Aneurysm, Vasculitis, Stroke

NCT04082910 2022-04-13

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Phase 1/2 Unknown

Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

NCT02126020 2017-04-07

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Phase 1/2 Withdrawn

Pemphigoid, Benign Mucous Membrane, Stevens-Johnson Syndrome, Syndrome